Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, isn’t without its risks. A recent study has found ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

While these medications offer unprecedented health benefits, they come with challenges like cost, non-adherence and lack of ...

The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

Hims & Hers ( HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk ( NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...

Millions of Americans are turning to popular GLP-1 drugs to help them lose weight — and while many have found weight loss success while taking these medicines, the number on ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

TD Cowen downgraded Hims & Hers Health to "Hold" from "Buy" citing a lack of near-term catalysts and concerns over the company’s weight loss revenue guidance in a post-compounded GLP-1 ...

Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy.

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.